Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A.

J Clin Endocrinol Metab. 2008 Mar;93(3):682-7. Epub 2007 Dec 11.

PMID:
18073307
2.

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.

Marsh DJ, Mulligan LM, Eng C.

Horm Res. 1997;47(4-6):168-78. Review.

PMID:
9167949
3.

Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment.

Boikos SA, Stratakis CA.

Histol Histopathol. 2008 Jan;23(1):109-16. Review.

PMID:
17952863
4.

Management of medullary thyroid carcinoma.

Jiménez C, Hu MI, Gagel RF.

Endocrinol Metab Clin North Am. 2008 Jun;37(2):481-96, x-xi. doi: 10.1016/j.ecl.2008.03.001. Review.

PMID:
18502338
5.

RAS proto-oncogene in medullary thyroid carcinoma.

Moura MM, Cavaco BM, Leite V.

Endocr Relat Cancer. 2015 Oct;22(5):R235-52. doi: 10.1530/ERC-15-0070. Review.

6.

Medullary thyroid carcinoma.

Pacini F, Castagna MG, Cipri C, Schlumberger M.

Clin Oncol (R Coll Radiol). 2010 Aug;22(6):475-85. doi: 10.1016/j.clon.2010.05.002. Review.

PMID:
20627492
7.

Medical management of metastatic medullary thyroid cancer.

Maxwell JE, Sherman SK, O'Dorisio TM, Howe JR.

Cancer. 2014 Nov 1;120(21):3287-301. doi: 10.1002/cncr.28858. Epub 2014 Jun 18. Review.

8.

Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.

Maia AL, Siqueira DR, Kulcsar MA, Tincani AJ, Mazeto GM, Maciel LM.

Arq Bras Endocrinol Metabol. 2014 Oct;58(7):667-700. English, Portuguese.

9.

Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.

Krajewska J, Olczyk T, Jarzab B.

Expert Rev Clin Pharmacol. 2016;9(1):69-79. doi: 10.1586/17512433.2016.1102052. Epub 2015 Nov 4. Review.

PMID:
26536165
10.

Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.

Chu YH, Lloyd RV.

Endocr Pathol. 2016 Aug 18. [Epub ahead of print] Review.

PMID:
27539727
11.

Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.

Vitale G, Dicitore A, Messina E, Sciammarella C, Faggiano A, Colao A.

Recent Pat Anticancer Drug Discov. 2016;11(3):275-82. Review.

PMID:
27306881
12.

Systemic treatment and management approaches for medullary thyroid cancer.

Ernani V, Kumar M, Chen AY, Owonikoko TK.

Cancer Treat Rev. 2016 Sep 10;50:89-98. doi: 10.1016/j.ctrv.2016.09.006. [Epub ahead of print] Review.

PMID:
27664392
13.

Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).

Grande E, Santamaría Sandi J, Capdevila J, Navarro González E, Zafón Llopis C, Ramón Y Cajal Asensio T, Gómez Sáez JM, Jiménez-Fonseca P, Riesco-Eizaguirre G, Galofré JC.

Clin Transl Oncol. 2016 Aug;18(8):769-75. doi: 10.1007/s12094-015-1465-x. Epub 2015 Dec 21. Review.

PMID:
26687366
Items per page

Supplemental Content

Write to the Help Desk